

# The Soluble $\alpha$ Chain of Interleukin-15 Receptor: A Proinflammatory Molecule Associated with Tumor Progression in Head and Neck Cancer

Cécile Badoual,<sup>1,2</sup> Grégory Bouchaud,<sup>8</sup> Nour El Houda Aguezny,<sup>1</sup> Erwan Mortier,<sup>8</sup> Stéphane Hans,<sup>3</sup> Alain Gey,<sup>4</sup> Fahima Fernani,<sup>1,4</sup> Séverine Peyrard,<sup>5</sup> Pierre Laurent-Puig,<sup>6</sup> Patrick Bruneval,<sup>2</sup> Xavier Sastre,<sup>7</sup> Ariane Plet,<sup>8</sup> Laure Garrigue-Antar,<sup>8</sup> Françoise Quintin-Colonna,<sup>1</sup> Wolf H. Fridman,<sup>4</sup> Daniel Brasnu,<sup>3</sup> Yannick Jacques,<sup>8</sup> and Eric Tartour<sup>1,4</sup>

<sup>1</sup>EA 4054 Université Paris Descartes, Faculté de Médecine; Ecole Nationale Vétérinaire d'Alfort, Maisons-Alfort, France; <sup>2</sup>Service d'Anatomie Pathologique, Hôpital Européen Georges Pompidou; <sup>3</sup>Department of Otorhinolaryngology-Head and Neck Surgery, Hôpital Européen Georges Pompidou; <sup>4</sup>Service d'Immunologie Biologique, Hôpital Européen Georges Pompidou; <sup>5</sup>Centre d'Investigations Cliniques, Assistance Publique des Hôpitaux de Paris; <sup>6</sup>Université Paris-Descartes, Institut National de la Santé et de la Recherche Médicale, UMR-S775; <sup>7</sup>Service d'Anatomie Pathologique, Institut Curie, Paris, France; and <sup>8</sup>Institut National de la Santé et de la Recherche Médicale, UMR 892, Groupe de Recherche Cytokines et Récepteurs, Institut de Biologie, Nantes, France

## Abstract

**Interleukin (IL)-15 is a proinflammatory cytokine, as it induces the production of inflammatory cytokines [IL-6, tumor necrosis factor  $\alpha$  (TNF $\alpha$ ), IL-17, etc.]. A correlation between high intratumoral IL-15 concentrations and poor clinical outcome in lung and head and neck cancer patients has been recently reported. The purpose of this study was to investigate the role of the soluble  $\alpha$  chain of IL-15 receptor (sIL-15R $\alpha$ ), a natural regulator of IL-15, in head and neck cancer. Fifty-three newly diagnosed untreated head and neck cancer patients were included in this study. Quantification of sIL-15R $\alpha$  was performed with a newly developed RIA. Increased serum sIL-15R $\alpha$  concentrations were found in head and neck cancer patients and were closely correlated with poor clinical outcome both in terms of locoregional control and survival even on multivariate analysis. sIL-15R $\alpha$  was mainly produced by tumor cells via proteolytic cleavage of IL-15R $\alpha$  mediated by ADAM-17. A correlation was observed between ADAM-17 expression in tumor cells and serum sIL-15R $\alpha$  concentrations. Surprisingly, sIL-15R $\alpha$  did not act *in vitro* as an IL-15 antagonist but rather as an enhancer of IL-15-induced proinflammatory cytokines (IL-6, TNF $\alpha$ , and IL-17) that may promote tumor progression. This new tumor evasion mechanism based on amplification of the intratumoral inflammatory reaction is probably not restricted to head and neck cancer, as other tumors have been shown to release sIL-15R $\alpha$ . Overall, these results support for the first time an original protumor role of sIL-15R $\alpha$  in cancer. [Cancer Res 2008;68(10):3907–14]**

## Introduction

Interleukin (IL)-15 is considered to be a proinflammatory cytokine, as it induces the production of cytokines [IL-6, tumor necrosis factor  $\alpha$  (TNF $\alpha$ ), IL-17, etc.], which play a role in various inflammatory processes (1–3). IL-15 is also a critical cytokine for

*in vivo* T-cell survival and function (4). It promotes the survival of CD8<sup>+</sup> T cells by protecting them from apoptosis (5, 6). IL-15 binds to the IL-15 receptor (IL-15R)  $\alpha$  chain with high affinity, and this chain, together with the IL-2 receptor (IL-2R)  $\beta$  chain and the IL-2R $\gamma$  chain subunits, constitutes a trimeric receptor for IL-15. IL-15R $\alpha$  can present IL-15 *in trans* to cells that express IL-2/IL-15R $\beta$  and IL-15R $\gamma$  but not IL-15R $\alpha$  (7). In preclinical models, IL-15 displays antitumor activity mainly mediated by CD8<sup>+</sup> T cells and natural killer (NK) cells (8, 9). In mice bearing leukemia, IL-15 abrogated tolerance of endogenous CD8<sup>+</sup> T cells and the rescued cells became effective in treating leukemia (10). IL-15 can also improve the *in vivo* antitumor activity of adoptively transferred CD8<sup>+</sup> T cells (11). In contrast, in other murine models, chronic stimulation of the IL-15 pathway led to the development of hematologic malignancies (12, 13). In humans, recent clinical studies reported a correlation between high intratumoral IL-15 concentrations and poor clinical outcome in patients with lung or head and neck cancers (14, 15). Head and neck cancer is heavily infiltrated by inflammatory immune cells (16). Head and neck cancer patients with increased serum concentrations of proinflammatory cytokines (IL-6, etc.), some of them regulated by IL-15, during the course of the disease have a poor survival (17). Molecules with the ability to inhibit the production of these cytokines improve the natural history of head and neck cancer (18). Because IL-15 is expressed in head and neck cancer and is associated with poor prognosis in these patients, we looked for the presence of specific regulator of IL-15 that may help to better understand its activity with the aim to modulate its function. We focused on soluble IL-15R $\alpha$  (sIL-15R $\alpha$ ) receptor because of the recent description of a natural soluble form of this receptor in humans and mice (19–21). In some situations, sIL-15R $\alpha$  behaves as an antagonist of IL-15 activity (19, 22, 23). We found increased concentrations of sIL-15R $\alpha$  in the serum of head and neck cancer patients, which were highly correlated with poor clinical outcome. Interestingly, sIL-15R $\alpha$  did not act as an IL-15 antagonist but rather as an enhancer of IL-15-induced proinflammatory cytokines that may promote tumor progression. Overall, these results support, for the first time, an original role of sIL-15R $\alpha$  in inflammation and cancer.

## Materials and Methods

**Patients.** Fifty-three newly diagnosed untreated patients with primary histologically proven head and neck squamous cell carcinoma (HNSCC) were included in this prospective study. Patient characteristics are

**Note:** Supplementary data for this article are available at Cancer Research Online (<http://cancerres.aacrjournals.org/>).

C. Badoual, G. Bouchaud, and N.E.H. Aguezny contributed equally to this work.

**Requests for reprints:** Eric Tartour, Hôpital Européen Georges Pompidou, Unité d'Immunologie Biologique, 20 Rue Leblanc, 75908 Paris Cedex 15, France. Phone: 33-1-56-09-39-42; Fax: 33-1-56-09-20-80; E-mail: eric.tartour@egp.aphp.fr.

©2008 American Association for Cancer Research.

doi:10.1158/0008-5472.CAN-07-6842

presented in Supplementary Table S1. Each patient's disease was staged according to the fifth edition of the International Union Against Cancer/American Joint Committee on Cancer system for head and neck cancer. Treatment modalities consisted of surgery, alone or combined with radiotherapy and chemotherapy. This study was conducted in accordance with French laws and after approval by the local ethics committee.

**Cell lines and blood cells.** The Fadu, SCC9, Cal27, and A253 cell lines derived from HNSCCs were obtained from the American Type Culture Collection. Cells were cultured in DMEM-F12 medium (Invitrogen) supplemented with L-glutamine. All cells were grown in 5% CO<sub>2</sub> at 37°C in a water-saturated atmosphere. Blood cells were collected from anonymous healthy donors at the Etablissement Français du Sang (EFS; Rungis, France) as buffy coat preparations after informed consent and following EFS guidelines. Peripheral blood mononuclear cells (PBMC) were isolated by density centrifugation on Ficoll-Hyperpaque gradients (Sigma-Aldrich). CD8<sup>+</sup> T cells were purified by positive selection using CD8-conjugated MACS beads (Miltenyi Biotec). The purified cells were composed of 90% to 95% CD8<sup>+</sup> T cells.

**Recombinant proteins and chemical reagents.** IL-15 and recombinant extracellular domain of human IL-15R $\alpha$  lacking the domain encoded by exon 3 and linked to human Fc were purchased from R&D Systems. Recombinant sIL-15R $\alpha$  comprising the complete extracellular domain of IL-15R $\alpha$  was produced as follows. The plasmid corresponding to the extracellular form of IL-15R $\alpha$  (pFB R15s) was generated by PCR using the sense primer 5'-CGGGATCCAGTCCAGCGGTGTCCTGTGG (nested restriction site underlined) and the antisense primer 5'-CTAGAGCGGC-GCTTACACAGTGGTGTGCTGT. After amplification, the sequence was ligated between the *Bam*H1 and *Not*I sites of the pFast Bac baculovirus expression vector (Invitrogen) and controlled (Genome Express). A sequence coding for the Flag epitope and Factor Xa binding site (DYKDDDDKIEGR) was added between the endogenous signal peptide and the coding sequence. The expression cassette was recombined in baculovirus DNA using the Bac to Bac expression system (Invitrogen). The recombinant baculoviruses were used to infect SF9 cells and sIL-15R $\alpha$  was expressed in the SF900 II medium and harvested 3 d after infection. For purification, the pH of the medium was increased to 8.5 with NaOH, and the medium was centrifuged at 10,000  $\times$  g for 15 min and filtered through a 0.45- $\mu$ m filter. The medium was concentrated and changed to 50 mmol/L Tris (pH 7.4) and 150 mmol/L NaCl in an Amicon chamber equipped with a 10,000 molecular weight cutoff membrane. The soluble receptor was purified on an anti-Flag-agarose affinity column (Sigma-Aldrich) and eluted with 0.1 mol/L glycine-HCl (pH 3.5). The purified protein was concentrated and the buffer was changed to PBS in Vivaspin (Sartorius). The purity of the protein was checked on Protein 200 Plus LabChip (Agilent Technologies) and Coomassie Blue-stained gel (Supplementary Fig. S1), and the concentration was determined by bicinchoninic acid (Pierce). Endotoxin levels determined by the limulus amebocyte lysate method were <1.0 endotoxin unit/ $\mu$ g recombinant protein. Phorbol 12-myristate 13-acetate (PMA) and ionomycin were purchased from Sigma-Aldrich.

**RIA for quantification of sIL-15R $\alpha$ .** Quantification of sIL-15R $\alpha$  was performed as previously described (19). Briefly, a sandwich RIA was set up in which the polyclonal goat anti-human IL-15R $\alpha$  antibody AF247 (R&D Systems) was used as capture antibody and radioiodinated monoclonal anti-human IL-15R $\alpha$  antibody M161, kindly provided by GenMab, was used as tracer. A purified recombinant sIL-15R $\alpha$  fusion protein as described above (24) was used as standard. AF247 was coated (5  $\mu$ g/mL; 50  $\mu$ L/well) onto high-adsorption Nunc MaxiSorp plates (breakable strips), distributed by Fisher Bioblock Scientific. Wells were saturated with 0.5% PBS-BSA for 15 min and sIL-15R $\alpha$ -containing samples (50  $\mu$ L/well) were incubated for 1 h at 4°C. The M161 monoclonal antibody (mAb), iodinated using the Iodogen method, was then added (1 nmol/L; 50  $\mu$ L/well) for 1 h at 4°C. Supernatants of each well were collected and wells were washed twice with PBS. The radioactivity associated with the wells (bound M161 fraction) and contained in the supernatants and washings (unbound M161 fraction) was determined. This assay measures with the same sensitivity, the sIL-15R $\alpha$  comprising the complete extracellular domain or deleted from the domain

encoded by exon 3 of IL-15R $\alpha$ . The present assay measures sIL-15R $\alpha$  receptor not bound to IL-15 (19).

**Induction of cytokines.** Cells were incubated in 24-well sterile plates with various combinations of cytokines and/or sIL-15R $\alpha$ . Supernatants were collected 24 or 72 h after stimulation. Cytokines were then measured by ELISA according to the manufacturer's recommendations. IL-6 and TNF $\alpha$  ELISA were obtained from Diaclone and IL-17 ELISA was purchased from Biosource.

**Flow cytometry.** Cells diluted in 0.1% PBS-azide were incubated for 30 min at 4°C with 5  $\mu$ g/mL goat anti-IL-15R $\alpha$  (R&D Systems) or isotype-matched control mAb. They were then washed twice with PBS-azide (0.1%) and incubated for 30 min at 4°C with 3  $\mu$ g/mL biotinylated rabbit anti-goat antibodies (DakoCytomation). After washings, cells were incubated for 30 min at 4°C with phycoerythrin-labeled streptavidin (DakoCytomation) and then analyzed on a FACSCalibur fluorocytometer (BD Biosciences). Data were acquired and analyzed with CellQuest software.

**Immunofluorescence staining.** Tissue samples obtained before any treatment at initial endoscopy or surgery were immediately frozen and stored at -80°C. Frozen specimens were sectioned at 4 to 6  $\mu$ m with a cryostat, placed on slides, air dried, and fixed for 10 min with 100% acetone. Before incubation with primary antibodies, the slides were treated with avidin/biotin blocker (Vector Laboratories) and Fc receptor was blocked by human serum (5%). The antibodies used for the various immunofluorescence stainings are described in Supplementary Table S2.

The various antibodies were diluted in PBS. Isotype-matched antibodies were used as negative controls. In each case, we checked that the secondary antibodies did not cross-react with the isotype or species of the other primary antibody immunoglobulin in the double immunofluorescence technique. Fluorescent images of mounted sections were analyzed with an epifluorescent microscope DMR (Leica Microsystems). Two authors (C.B. and E.T.), blinded for clinical data, independently scored the slides in at least five fields using a 40 $\times$  objective.

**Reverse transcription-PCR amplification.** Total cellular RNAs were extracted using the Tri-reagent kit from Ambion (Applied Biosystems). Two micrograms of total cellular RNAs were reverse transcribed with oligo(dT) primers using the first-strand cDNA synthesis kit (Roche Molecular Biochemicals). PCR was performed as previously described (25). The following oligonucleotides were used:  $\beta$ -actin, TCGTCGACACGGC-TCCGGCATGTGC (sense) and TTCTCCAGGGAGGAGCTGGAAGCAGC (antisense); ADAM-17, ACCTGAAGAGCTTGTTCATCGAG (sense) and CCATGAAGTGTTCGATAGATGTC (antisense); hypoxanthine-guanine phosphoribosyltransferase (HGPRT), CCTTGGTCAGGCAGTATAATCC (sense) and TTGTATTTTGCTTTTCCAGTTTCAC (antisense); IL-15, GGA-TTTACCGTGGCTTTGAGTAATGAG (sense) and ACAATTTGGACAATATG-TACAAAA (antisense); IL-6, ACGAATTCAACAACAATTCGGTACA (sense) and CATCTAGATTCTTTGCTTTTCTGTC (antisense); TNF $\alpha$ , GCGAATT-CCCTCCTGGCCAATGGCGTGG (sense) and CTAAGCTGGGTTCC-GACCCTAAGCCCCC (antisense). Two couples of IL-15R $\alpha$  primers were selected. IL-15R $\alpha$  sense 1: CATGTCCGTGGAACACGCAG (hybridizing to cDNA sequence encoded by exon 2, nucleotides 189–209); IL-15R $\alpha$  antisense 1: AGGAGAGACACAGCGCTCAG (hybridizing to cDNA sequence encoded by exon 6, nucleotides 733–753); IL-15R $\alpha$  sense 2: GAGACCCTGCCCTGG-TTCACCA (hybridizing to cDNA sequence encoded by exon 3, nucleotides 366–387); IL-15R $\alpha$  antisense 2: TCATAGGTGGTGGAGAGCAGT (hybridizing to cDNA sequences encoded by exon 7, nucleotides 867–886). This last couple of primers was designed to detect alternative splicing of transmembrane exon 6, which may encode sIL-15R $\alpha$  receptor as previously described for other soluble cytokine receptors.

**IL-15:IL-15R $\alpha$  cross-linking.** sIL-15R $\alpha$  was purified and concentrated from supernatants of tumor cell lines by affinity purification using the anti-IL-15R $\alpha$  mAb M161, as previously described (19). Samples (recombinant IL-15R $\alpha$  or purified sIL-15R $\alpha$  from supernatants) were incubated with iodinated IL-15 (2 nmol/L), cross-linked with the homobifunctional cross-linker EGS (Sigma-Aldrich), and subjected to 10% SDS-PAGE and autoradiography (PhosphorImager 445 SI, Molecular Dynamics, Inc.).

**Statistical analysis.** Survival variables were estimated using the Kaplan-Meier method and compared by the log-rank test for categorical variables

and using the Cox model and the associated Wald  $\chi^2$  statistic for quantitative variables.

Multivariate analysis using the Cox proportional hazard model determined the influence of each variable, when adjusted to others, on locoregional control (relapse-free survival) and overall survival. The level of significance was set at  $P \leq 0.05$ .

Overall survival was defined as the time from initial diagnosis until death or until last follow-up (right censored data).

Locoregional control was calculated from the end of treatment and defined as the absence or either persistent or recurrent disease at the primary site or in the cervical lymph nodes. Patients with persistent disease at the end of treatment were considered to have experienced failure at time zero. Patients with no signs of relapse were censored at the time of last follow-up or death. The median follow-up for the whole population was 24 mo.

The Mann-Whitney  $U$  test was also used to assess whether samples of observations came from the same distribution.

## Results

**Increased serum sIL-15R $\alpha$  levels in patients with head and neck cancers.** A significant increase in the concentrations of sIL-15R $\alpha$  was observed in serum samples collected from head and neck cancer patients at diagnosis before therapy compared with those of healthy donors (Fig. 1). Mean concentrations of sIL-15R $\alpha$  were 5.8 pmol/L for head and neck cancer patients and 0.35 pmol/L for healthy donors. sIL-15R $\alpha$  was detected in serum in 35 of 53 (66%) head and neck cancer patients versus 15% (6 of 40) in healthy subjects ( $P < 0.0001$ ; Fig. 1). As expected, we did not detect IL-15 in the serum of these patients, as free IL-15 is rarely detectable in biological fluids.

**Prognostic value of serum sIL-15R $\alpha$  level on the locoregional control and overall survival rates in HNSCC patients.** To assess the clinical significance of sIL-15R $\alpha$  dysregulation in these cancer patients, the prognostic value of serum sIL-15R $\alpha$  levels was determined. Serum sIL-15R $\alpha$  levels were significantly correlated with both locoregional control and survival. The locoregional control rate at 12 months was 78% for head and neck patients with no detectable serum sIL-15R $\alpha$  versus only 48% for cancer patients with detectable sIL-15R $\alpha$  ( $P = 0.04$ ; Fig. 2A). When considered as a continuous variable, serum sIL-15R $\alpha$  levels were also negatively correlated with locoregional control ( $P = 0.01$ ; Fig. 2B). In addition,


serum sIL-15R $\alpha$  levels were positively correlated with shorter survival when considered as a continuous variable ( $P = 0.003$ ; Fig. 2C). The 12-month survival rate in patients with no serum sIL-15R $\alpha$  levels was 89% versus 69% for patients with detectable sIL-15R $\alpha$  levels ( $P = 0.04$ ; Fig. 2D). Multivariate analysis, including tumor stage, tumor-node-metastasis (TNM) grading, and serum sIL-2R $\alpha$  levels considered as a powerful prognosis marker (26), showed that the only significant prognostic factor independently related to locoregional control was the serum sIL-15R $\alpha$  level ( $P = 0.0065$ ; relative risk, 1.078). On Cox multivariate analysis, only serum sIL-15R $\alpha$  levels influenced overall survival probability ( $P = 0.0059$ ; relative risk, 1.086; Supplementary Table S3).


**Head and neck tumor cells secrete sIL-15R $\alpha$  and express membrane IL-15R $\alpha$ .** The difference in sIL-15R $\alpha$  concentrations observed between cancer patients and healthy subjects led us to assess whether sIL-15R $\alpha$  may originate from tumor cells. We showed that, *in vitro*, tumor cell lines derived from HNSCC produced high levels of sIL-15R $\alpha$  (Fig. 3). This secretion is increased by PMA-ionomycin (Supplementary Fig. S2). In contrast with other tumors (27), these cells did not secrete or express membrane-bound IL-15 (data not shown). In contrast, statistically significant lower levels of sIL-15R $\alpha$  were secreted by resting PBMC from healthy donors compared with tumor cells ( $P < 0.01$ ; Fig. 3). Because it has been shown that murine sIL-15R $\alpha$  is generated by cleavage of membrane IL-15R $\alpha$  (19, 20), we analyzed expression of the IL-15R by these tumor cell lines *in vitro* and directly *in situ* in biopsies from head and neck cancer patients.

In a first series of experiments, we showed that tumor cell lines expressed two transcripts of IL-15R $\alpha$  mRNA (Fig. 4A). These PCR products were eluted and sequenced. The 564-bp PCR product corresponded to the wild-type isoform comprising the full ectodomain of IL-15R $\alpha$ . The 464-bp PCR product was derived from an isoform with deletion of the exon 3 of IL-15R $\alpha$  mRNA (Fig. 4A). The same isoforms of IL-15R $\alpha$  were present in PBMC (Fig. 4A). Characterization of the sIL-15R $\alpha$  protein showed that the wild-type isoform not deleted from domain encoded by exon 3 was the predominant form detected in the supernatant of these tumor cells (Supplementary Fig. S3A).

Fluorescence-activated cell sorting analysis confirmed the membrane expression of IL-15R $\alpha$  by these tumor cell lines

**Figure 1.** Increased serum levels of sIL-15R $\alpha$  in patients with head and neck cancers. sIL-15R $\alpha$  concentrations were determined using a RIA assay in serum samples from 53 head and neck cancer patients collected at diagnosis before the start of therapy. Forty serum samples from healthy donors were included as controls.






**Figure 2.** Locoregional control and survival at 24 mo for patients with HNSCC in relation to their serum sIL-15R $\alpha$  levels. *A* and *B*, relationships between locoregional control and serum sIL-15R $\alpha$  levels. *C* and *D*, correlation between survival and serum sIL-15R $\alpha$  levels. *B* and *C*, dashed lines, upper and lower 95% confidence interval.

(Fig. 4B). To assess the *in vivo* relevance of these results, tissues from head and neck cancer patients or normal mucosae were stained with anti-IL-15R $\alpha$  antibodies. Tumor cells were clearly labeled with anti-IL-15R $\alpha$  antibodies (Fig. 4C, left). This expression of IL-15R $\alpha$  was found in 17 of 48 tumors tested. In contrast, normal epithelium did not significantly express IL-15R $\alpha$  (Fig. 4C, right). It should be noted that isolated cells with a macrophage morphology in both tumor stroma and normal mucosa also seemed to express IL-15R $\alpha$  (Fig. 4C).


As it has been reported that ADAM-17 was responsible for the cleavage of IL-15R $\alpha$  (20), we wondered whether tumor cells expressed this metalloproteinase. Reverse transcription-PCR analysis showed mRNA expression of ADAM-17 in all three head and neck tumor cell lines tested (Fig. 5A). Double immunofluorescence analysis on fresh biopsies of head and neck cancers extended this result to cancer tissues. Tumor cells were clearly costained with anti-AE1/AE3 antibodies (Fig. 5B, middle and right), a pancytokeratin marker used to identify tumor cells, and anti-ADAM-17 (Fig. 5B, left and right).

Using primers overlapping the transmembrane exon to track putative alternative splicing of this exon to generate mRNA encoding sIL-15R $\alpha$ , no specific mRNA for sIL-15R $\alpha$  was detected (Supplementary Fig. S2B). In addition, as previously shown in murine models (19, 20), ADAM-17 small interfering RNA (siRNA) partially inhibited the release of sIL-15R $\alpha$  in supernatants of head and neck tumor cell lines (Supplementary Fig. S4). Overall, these results support previous data obtained in murine model that sIL-15R $\alpha$  released by tumor cells is produced by cleavage of IL-15R $\alpha$  mediated by ADAM-17 (20).

In addition, a significant correlation was found between ADAM-17 expression in tumors and serum sIL-15R $\alpha$  levels, as the mean serum sIL-15R $\alpha$  concentration was 1.35 pmol/L when ADAM-17 was expressed by <50% of tumor cells, whereas this concentration increased to 8.65 pmol/L in patients with high tumor expression of ADAM-17 (Supplementary Table S4). No correlation was found between serum sIL-15R $\alpha$  concentration and IL-15R $\alpha$  expression by



**Figure 3.** Head and neck cancer cell lines produced high levels of sIL-15R $\alpha$ . Head and neck cancer cells (SCC9, Cal27, Fadu, and A253) and three PBMCs derived from healthy donors were cultured for 24 h. Supernatants were then collected and sIL-15R $\alpha$  was measured by a RIA assay. All measurements were performed in duplicate and each experiment was performed twice.




**Figure 4.** Tumor cells from head and neck patients express IL-15R $\alpha$ . *A*, three cDNA derived from mRNA extracted from three head and neck cell lines (Fadu, SCC9, and A253) or PBMC were amplified by PCR using oligonucleotide primers specific for  $\beta$ -actin and IL-15R $\alpha$ . Amplified PCR products were loaded onto a 2% agarose gel and stained with ethidium bromide for UV visualization. *B*, two head and neck cancer cell lines (Fadu and A253) were stained with goat anti-IL-15R $\alpha$  polyclonal antibody. Polyclonal isotype control antibodies were included in each experiment. The labeling was analyzed by fluorescence-activated cell sorter. *C*, frozen tissues derived from head and neck cancer biopsies (*left* and *middle*) or normal head and neck mucosa (*right*) were stained with primary goat antibodies against IL-15R $\alpha$  (*left* and *right*) or normal isotype control (*middle*). The reaction was revealed with biotinylated rabbit anti-goat IgG and then CyTM2-labeled streptavidin.

tumor cells (data not shown). These results therefore suggest that ADAM-17 is a critical factor for the release of sIL-15R $\alpha$  *in vivo*.


**sIL-15R $\alpha$  increased IL-15 activity on the production of proinflammatory cytokines.** As two sIL-15R $\alpha$  isoforms were expressed by tumor cells, although one of them was predominant at the protein level (Fig. 4; Supplementary Fig. S3A), the role of these two isoforms on the modulation of IL-15 activity was tested *in vitro* in various models. IL-15 is known to play a major role on CD8 $^+$  T-cell survival and homeostasis, which may enhance their antitumor activity (28). Unexpectedly, both isoforms were found to increase IL-15-induced proliferation of purified CD8 $^+$  T cells

(Fig. 6A). This potentiation of the activity of IL-15 was seen at various doses of IL-15 ranging from 10 to 100 ng/mL (Fig. 6A; data not shown). No effect of sIL-15R $\alpha$  alone on CD8 $^+$  T-cell proliferation was recorded (data not shown). To check for the specificity of the action of sIL-15R $\alpha$ , these soluble IL-15Rs were shown not to have any activity on IL-2-dependent CD8 $^+$  T-cell proliferation (Fig. 6A).

IL-15 has been reported to increase the production of several proinflammatory cytokines, such as IL-6 and TNF $\alpha$  (1, 2). Low doses of IL-15 up to 10 ng/mL were not efficient to induce significant levels of IL-6 and TNF $\alpha$  by human PBMC and high doses of IL-15 (100 ng/mL) were required to elicit large amounts of IL-6



**Figure 5.** Expression of ADAM-17 by head and neck cancer cells. *A*, cDNA derived from mRNA extracted from three head and neck cancer cell lines were amplified by primers specific for ADAM-17 and HGPRT. Amplified PCR products were loaded onto a 2% agarose gel and stained with ethidium bromide for UV visualization. *B*, tissues derived from head and neck cancer specimens were stained with antibodies to human ADAM-17 and pancytokeratin AE1/AE3. *Left* and *middle*, results of simple immunofluorescence acquisition with each antibody; *right*, double immunofluorescence staining. *Yellow*, colocalization between the two markers recognized by the specific antibodies. Isotype control antibodies gave no staining.



**Figure 6.** sIL-15R $\alpha$  increased IL-15 activity on CD8<sup>+</sup> T-cell proliferation and production of inflammatory cytokines. **A**, purified CD8<sup>+</sup> T cells ( $10^5$ ) were seeded on 96-well plates and cultured in medium or IL-15 (10 ng/mL) or IL-2 (1,000 IU/mL) alone ( $\square$ ) or in combination with sIL-15R $\alpha$  (350 ng/mL) comprising either the full ectodomain of sIL-15R $\alpha$  or deleted from the domain encoded by exon 3 ( $\blacksquare$ ). **B to D**, PBMCs ( $2 \times 10^5$ /mL) were stimulated or not with IL-15 [10 ng/mL (**B** and **C**) or 100 ng/mL (**D**)] in combination with the two kinds of sIL-15R $\alpha$  described in **A**. Seventy-two hours later, supernatants were collected and concentrations of IL-6 (**B**), TNF $\alpha$  (**C**), and IL-17 (**D**) were measured by ELISA. These results are representative from three experiments performed with three different PBMCs.

and TNF $\alpha$  (Fig. 6B and C; data not shown). In contrast, in combination with both sIL-15R $\alpha$  isoforms, low doses of IL-15 (10 ng/mL) were shown to markedly increase the production of IL-6 and TNF $\alpha$  by PBMC (Fig. 5B and C). The secretion of these cytokines was only observed in the presence of the IL-15/sIL-15R $\alpha$  complex, as addition of sIL-15R $\alpha$  alone had no effect (Fig. 6B and C). All recombinant molecules used were tested for the absence of significant lipopolysaccharide contamination (<1.0 endotoxin unit/ $\mu$ g recombinant protein). The possible role of sIL-15R $\alpha$  on the induction of IL-17, a proinflammatory cytokine with protumor activity (29, 30) produced by a subpopulation of CD4<sup>+</sup> T cells (TH 17 cells) and previously shown to be regulated by IL-15, was also assessed. As shown in Fig. 6D, high doses of IL-15 (100 ng/mL) were required to elicit weak production of IL-17, supporting previous studies reporting that CD4<sup>+</sup> T cells are less sensitive to IL-15 than other T and NK cells. sIL-15R $\alpha$  synergized with IL-15 to greatly enhance the secretion of IL-17. Both isoforms of sIL-15R $\alpha$  therefore synergized with IL-15 to enhance the release of proinflammatory cytokines. These data seem to be relevant *in vivo* as we showed that mRNA coding for IL-15, sIL-15R $\alpha$ , IL-6, and TNF $\alpha$  could be expressed in the same biopsy of head and neck cancer patients (Supplementary Fig. S5).

## Discussion

This study reports increased serum sIL-15R $\alpha$  levels in head and neck cancer patients compared with healthy subjects. Serum sIL-15R $\alpha$  levels were strongly associated with poor clinical outcome both in terms of locoregional control and survival. On multivariate analysis, this biomarker was more powerful than the conventional clinical variables (TNM) used for the initial staging of head and neck cancer patients. Surprisingly, sIL-15R $\alpha$  did not seem to act via inhibition of IL-15 but rather as an amplifier of IL-15 activity. We showed that sIL-15R $\alpha$  synergized with IL-15 to

enhance the production of proinflammatory cytokines. sIL-15R $\alpha$  was first described as an antagonist of IL-15 (22, 23), but recent data have shown that administration of soluble IL-15/IL-15R $\alpha$  complexes markedly enhanced IL-15 half-life and bioavailability *in vivo* (31–33), which supports our results. sIL-15R $\alpha$  does not seem to exert any synergy with IL-15 on cells expressing the high-affinity IL-15R (19). However, it promotes IL-15 action on cells expressing intermediate- or low-affinity IL-15R (34). Thus, in addition to the ability of membrane-anchored IL-15R $\alpha$  to present IL-15 in *trans* to neighboring cells during cell-to-cell contact (7), IL-15-sIL-15R $\alpha$  heterocomplexes may also perform a similar function of IL-15 transpresentation in a soluble form. Similar observations have been reported with soluble IL-6 receptors, as shedding of sIL-6Rgp80 from colon adenocarcinoma cells allowed the formation of IL-6/sIL-6R complexes, which could lead to tumor growth of colon carcinoma cells expressing gp130 but not IL-6Rgp80 (35). It should be noted that, in the present study, IL-15 alone or combined with sIL-15R $\alpha$  did not exert any effect on the growth of head and neck tumor cells (data not shown).

In our study, tumor cells only secreted sIL-15R $\alpha$  but the formation of sIL-15R $\alpha$ -IL-15 *in situ* is expected, as high levels of IL-15 have been reported in biopsies derived from head and neck cancers (15). Because tumor cells did not seem to produce IL-15, monocytes or dendritic cells present in tumor stroma may secrete this cytokine. We could not also exclude that membrane IL-15 expressed in monocytes is the target of sIL-15R $\alpha$ . From preclinical studies, IL-15 was considered to be an antitumor cytokine mainly due to its role in the activation of antitumor CD8<sup>+</sup> T cells promoting the expansion of CTL with high avidity (9, 10, 36). This activity of IL-15 may be not predominant in head and neck cancer patients as antitumor function of T lymphocytes is often compromised (37, 38) and CD8<sup>+</sup> T lymphocytes seem to be particularly sensitive to apoptosis in these patients (39). However, sIL-15R $\alpha$  amplified the IL-15-induced production of various proinflammatory cytokines,

such as IL-6, TNF $\alpha$ , and IL-17, which may promote tumor progression. TNF $\alpha$  and IL-6 are known to act as growth factors for many tumor cells. They are required for the development of tumors induced by chemical carcinogens. IL-6 activates signal transducers and activators of transcription 3, which blocks apoptosis of cancer cells and contributes to the tolerant state of dendritic cells in the tumor microenvironment (40). IL-17 also promotes tumor progression partly via its proangiogenesis effect (29, 30). These *in vitro* results on the role of IL-15 amplified by sIL-15R $\alpha$  in the secretion of inflammatory cytokines seem relevant with respect to the *in vivo* inflammatory environment of these head and neck cancer patients, as mean concentrations of proinflammatory cytokines, such as IL-6, are increased in these patients (41). We detected serum IL-6 levels suggesting an ongoing inflammatory reaction in some patients included in this study (data not shown). The detrimental role of these inflammatory cytokines for the host is documented by preclinical and clinical data. In mice implanted with murine head and neck tumors, orally delivered lactoferrin, an iron-binding secretory protein, inhibited tumor growth. This effect seemed to be mediated by the ability of lactoferrin to inhibit the cellular release of proinflammatory and prometastatic cytokines (18). Increased serum concentrations of proinflammatory cytokines have been correlated with poor outcome in head and neck cancer patients (17). Other activities of IL-15 that may contribute to the protumor activity of this cytokine include its role in tumor protection from apoptosis, its action on vascular endothelial cells to induce angiogenesis, and its ability to enhance cell motility and invasiveness of cancer cells (42). This protumor role of IL-15, possibly amplified by sIL-15R $\alpha$ , has been supported by recent clinical prognostic results. Using microarray analysis, expression of IL-15 in biopsies of oral cancer was associated with the development of metastasis in these patients (15).

More generally, murine models and epidemiologic studies have established that chronic inflammation caused by infectious microorganisms or chemical irritants orchestrates a tumor-supporting microenvironment that is indispensable in the neoplastic process (43–45). Recent reports suggest that inflammatory cytokines are more likely to contribute to tumor growth and progression than to mount an effective host antitumor immune response (46, 47), as also suggested by this study, where IL-15-sIL-15R $\alpha$  complex seemed to be an important player coordinating the induction of the proinflammatory cascade.

As previously reported for other cytokines (47), IL-15 could be considered to be ambivalent cytokine in the modulation of tumor growth with a fine balance between antitumor activities mainly mediated by CD8<sup>+</sup> T and NK cells and protumor activities mediated by amplification of inflammatory reactions.

The increased concentrations of sIL-15R $\alpha$  in head and neck cancer patients could be explained by the release of sIL-15R $\alpha$  by tumor cells. Tumor cells express IL-15R $\alpha$  *in vitro* and *in vivo*.

Expression of this receptor was not found in normal corresponding mucosa, suggesting dysregulation of the expression of this receptor with malignant transformation. An increased expression of IL-15R $\alpha$  by epithelial cells in benign prostatic hyperplasia compared with normal prostate has also been previously observed (48).

With respect to the mechanisms of sIL-15R $\alpha$  production, its release seems to be dependent on proteolytic cleavage, as no mRNA was detected with alternative splicing of transmembrane exon encoding sIL-15R $\alpha$ . Recently, sIL-15R $\alpha$  only comprising the Sushi domains of the receptor was shown to be generated by alternative splicing mechanism within intron 2 of IL-15R $\alpha$  in mice (21). The predicted molecular mass of this isoform was 12 kDa. We could not completely exclude the presence of a similar soluble Sushi isoform in human, although this study and others found that the human sIL-15R $\alpha$  had a molecular mass of about 42 to 45 kDa (Supplementary Fig. S3; ref. 19).

In addition, as previously described (20), various arguments converge to support the role of ADAM-17 in the shedding of sIL-15R $\alpha$ : (a) head and neck tumor cell lines and tumor cells *in situ* expressed ADAM-17, (b) ADAM-17 inhibitors decreased the *in vitro* release of sIL-15R $\alpha$  by head and neck tumor cell lines, and (c) a correlation was shown between ADAM-17 expression by tumor cells *in situ* and serum sIL-15R $\alpha$  levels. ADAM-17 has been postulated as a tumor promoter. Targeting this protease with small molecular inhibitors or siRNAs reverted the malignant phenotype in a breast cancer cell line by preventing mobilization of two crucial growth factors, transforming growth factor- $\alpha$  and amphiregulin, which bind to erbB (49). Oral administration of a small-molecule inhibitor of ADAM-17 to tumor-bearing mice resulted in a significant decrease of tumor proliferation (50). Inhibition of cleavage of sIL-15R $\alpha$  by these ADAM-17 inhibitors may counteract this new tumor evasion mechanism and improve the prognosis of these cancer patients. This new tumor evasion mechanism, possibly dependent on amplification of the intratumoral inflammatory reaction, reported in this study for head and neck cancers could also be potentially extended to leukemia and other solid tumors, which have been shown to express and release sIL-15R.

## Disclosure of Potential Conflicts of Interest

No potential conflicts of interest were disclosed.

## Acknowledgments

Received 12/26/2007; revised 3/3/2008; accepted 3/12/2008.

**Grant support:** European Community under the Sixth Framework Programme (grant N° LSHC-2005-518234, "Cancerimmunotherapy"), Institut National du Cancer, Cancéropole, Ligue contre le Cancer (comité du Val de Marne), Pôle de Compétitivité Médicines (Immucan project), and CICBT AP-HP/Institut National de la Santé et de la Recherche Médicale (E. Tartour) and Région Pays de Loire (grant CIMATH) and Cancéropole Grand-Ouest (grant MabImpact; Y. Jacques).

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked *advertisement* in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

## References

- McInnes IB, Leung BP, Sturrock RD, Field M, Liew FY. Interleukin-15 mediates T cell-dependent regulation of tumor necrosis factor- $\alpha$  production in rheumatoid arthritis. *Nat Med* 1997;3:189–95.
- Ohteki T, Tada H, Ishida K, et al. Essential roles of DC-derived IL-15 as a mediator of inflammatory responses *in vivo*. *J Exp Med* 2006;203:2329–38.
- Ziolkowska M, Koc A, Luszczekiewicz G, et al. High levels of IL-17 in rheumatoid arthritis patients: IL-15 triggers *in vitro* IL-17 production via cyclosporin A-sensitive mechanism. *J Immunol* 2000;164:2832–8.
- Waldmann TA. The biology of interleukin-2 and interleukin-15: implications for cancer therapy and vaccine design. *Nat Rev Immunol* 2006;6:595–601.
- Bulfone-Paus S, Ungureanu D, Pohl T, et al. Interleukin-15 protects from lethal apoptosis *in vivo*. *Nat Med* 1997;3:1124–8.
- Yajima T, Yoshihara K, Nakazato K, et al. IL-15 regulates CD8<sup>+</sup> T cell contraction during primary infection. *J Immunol* 2006;176:507–15.
- Dubois S, Mariner J, Waldmann TA, Tagaya Y. IL-15R $\alpha$  recycles and presents IL15 *in trans* to neighboring cells. *Immunity* 2002;17:537–47.
- Yajima T, Nishimura H, Wajjwalku W, et al. Overexpression of interleukin-15 *in vivo* enhances antitumor activity against MHC class I-negative and -positive malignant melanoma through augmented

- NK activity and cytotoxic T-cell response. *Int J Cancer* 2002;99:573–8.
9. Kobayashi H, Dubois S, Sato N, et al. Role of trans-cellular IL-15 presentation in the activation of NK cell-mediated killing, which leads to enhanced tumor immunosurveillance. *Blood* 2005;105:721–7.
  10. Teague RM, Sather BD, Sacks JA, et al. Interleukin-15 rescues tolerant CD8<sup>+</sup> T cells for use in adoptive immunotherapy of established tumors. *Nat Med* 2006;12:335–41.
  11. Klebanoff CA, Finkelstein SE, Surman DR, et al. IL-15 enhances the *in vivo* antitumor activity of tumor-reactive CD8<sup>+</sup> T cells. *Proc Natl Acad Sci U S A* 2004;101:1969–74.
  12. Fehniger TA, Suzuki K, Ponnappan A, et al. Fatal leukemia in interleukin 15 transgenic mice follows early expansions in natural killer and memory phenotype CD8<sup>+</sup> T cells. *J Exp Med* 2001;193:219–31.
  13. Baldassarre G, Fedele M, Battista S, et al. Onset of natural killer cell lymphomas in transgenic mice carrying a truncated HMGI-C gene by the chronic stimulation of the IL-2 and IL-15 pathway. *Proc Natl Acad Sci U S A* 2001;98:7970–5.
  14. Seike M, Yanaihara N, Bowman ED, et al. Use of a cytokine gene expression signature in lung adenocarcinoma and the surrounding tissue as a prognostic classifier. *J Natl Cancer Inst* 2007;99:1257–69.
  15. Nguyen ST, Hasegawa S, Tsuda H, et al. Identification of a predictive gene expression signature of cervical lymph node metastasis in oral squamous cell carcinoma. *Cancer Sci* 2007;98:740–6.
  16. Badoual C, Hans S, Rodriguez J, et al. Prognostic value of tumor-infiltrating CD4<sup>+</sup> T-cell subpopulations in head and neck cancers. *Clin Cancer Res* 2006;12:465–72.
  17. Allen C, Duffy S, Teknos T, et al. Nuclear factor- $\kappa$ B-related serum factors as longitudinal biomarkers of response and survival in advanced oropharyngeal carcinoma. *Clin Cancer Res* 2007;13:3182–90.
  18. Wolf JS, Li G, Varadhachary A, et al. Oral lactoferrin results in T cell-dependent tumor inhibition of head and neck squamous cell carcinoma *in vivo*. *Clin Cancer Res* 2007;13:1601–10.
  19. Mortier E, Bernard J, Plet A, Jacques Y. Natural, proteolytic release of a soluble form of human IL-15 receptor  $\alpha$ -chain that behaves as a specific, high affinity IL-15 antagonist. *J Immunol* 2004;173:1681–8.
  20. Budagian V, Bulanova E, Orinska Z, et al. Natural soluble interleukin-15R $\alpha$  is generated by cleavage that involves the tumor necrosis factor- $\alpha$ -converting enzyme (TACE/ADAM17). *J Biol Chem* 2004;279:40368–75.
  21. Bulanova E, Budagian V, Duitman E, et al. Soluble interleukin IL-15R $\alpha$  is generated by alternative splicing or proteolytic cleavage and forms functional complexes with IL-15. *J Biol Chem* 2007;282:13167–79.
  22. Ruckert R, Brandt K, Braun A, et al. Blocking IL-15 prevents the induction of allergen-specific T cells and allergic inflammation *in vivo*. *J Immunol* 2005;174:5507–15.
  23. Smith XG, Bolton EM, Ruchatz H, et al. Selective blockade of IL-15 by soluble IL-15 receptor  $\alpha$ -chain enhances cardiac allograft survival. *J Immunol* 2000;165:344–450.
  24. Mortier E, Quemener A, Vusio P, et al. Soluble interleukin-15 receptor  $\alpha$  (IL-15R $\alpha$ )-sushi as a selective and potent agonist of IL-15 action through IL-15R $\beta$ / $\gamma$ . Hyperagonist IL-15  $\times$  IL-15R $\alpha$  fusion proteins. *J Biol Chem* 2006;281:1612–9.
  25. Benchetrit F, Ciree A, Vives V, et al. Interleukin-17 inhibits tumor cell growth by means of a T-cell-dependent mechanism. *Blood* 2002;99:2114–21.
  26. Tartour E, Mosseri V, Jouffroy T, et al. Serum soluble interleukin-2 receptor concentrations as an independent prognostic marker in head and neck cancer. *Lancet* 2001;357:1263–4.
  27. Wittnebel S, Da Rocha S, Giron-Michel J, et al. Membrane-bound interleukin (IL)-15 on renal tumor cells rescues natural killer cells from IL-2 starvation-induced apoptosis. *Cancer Res* 2007;67:5594–9.
  28. Anichini A, Scarito A, Molla A, Parmiani G, Mortarini R. Differentiation of CD8<sup>+</sup> T cells from tumor-invaded and tumor-free lymph nodes of melanoma patients: role of common  $\gamma$ -chain cytokines. *J Immunol* 2003;171:2134–41.
  29. Tartour E, Fossiez F, Joyeux I, et al. Interleukin 17, a T-cell-derived cytokine, promotes tumorigenicity of human cervical tumors in nude mice. *Cancer Res* 1999;59:3698–704.
  30. Numasaki M, Fukushi J, Ono M, et al. Interleukin-17 promotes angiogenesis and tumor growth. *Blood* 2003;101:2620–7.
  31. Stoklasek TA, Schluns KS, Lefrancois L. Combined IL-15/IL-15R $\alpha$  immunotherapy maximizes IL-15 activity *in vivo*. *J Immunol* 2006;177:6072–80.
  32. Rubinstein MP, Kovar M, Purton JF, et al. Converting IL-15 to a superagonist by binding to soluble IL-15R $\alpha$ . *Proc Natl Acad Sci U S A* 2006;103:9166–71.
  33. Bernard J, Harb C, Mortier E, et al. Identification of an interleukin-15 $\alpha$  receptor-binding site on human interleukin-15. *J Biol Chem* 2004;279:24313–22.
  34. Giron-Michel J, Giuliani M, Fogli M, et al. Membrane-bound and soluble IL-15/IL-15R $\alpha$  complexes display differential signaling and functions on human hematopoietic progenitors. *Blood* 2005;106:2302–10.
  35. Becker C, Fantini MC, Schramm C, et al. TGF- $\beta$  suppresses tumor progression in colon cancer by inhibition of IL-6 *trans*-signaling. *Immunity* 2004;21:491–501.
  36. Oh S, Perera LP, Burke DS, Waldmann TA, Berzofsky JA. IL-15/IL-15R $\alpha$ -mediated avidity maturation of memory CD8<sup>+</sup> T cells. *Proc Natl Acad Sci U S A* 2004;101:15154–9.
  37. Young MR. Protective mechanisms of head and neck squamous cell carcinomas from immune assault. *Head Neck* 2006;28:462–70.
  38. Reichert TE, Strauss L, Wagner EM, Gooding W, Whiteside TL. Signaling abnormalities, apoptosis, and reduced proliferation of circulating and tumor-infiltrating lymphocytes in patients with oral carcinoma. *Clin Cancer Res* 2002;8:3137–45.
  39. Hoffmann TK, Dworacki G, Tsukihito T, et al. Spontaneous apoptosis of circulating T lymphocytes in patients with head and neck cancer and its clinical importance. *Clin Cancer Res* 2002;8:2553–62.
  40. Yu H, Kortylewski M, Pardoll D. Crosstalk between cancer and immune cells: role of STAT3 in the tumour microenvironment. *Nat Rev Immunol* 2007;7:41–51.
  41. Druzgal CH, Chen Z, Yeh NT, et al. A pilot study of longitudinal serum cytokine and angiogenesis factor levels as markers of therapeutic response and survival in patients with head and neck squamous cell carcinoma. *Head Neck* 2005;27:771–84.
  42. Kuniyasu H, Ohmori H, Sasaki T, et al. Production of interleukin 15 by human colon cancer cells is associated with induction of mucosal hyperplasia, angiogenesis, and metastasis. *Clin Cancer Res* 2003;9:4802–10.
  43. Colombo MP, Mantovani A. Targeting myelomonocytic cells to revert inflammation-dependent cancer promotion. *Cancer Res* 2005;65:9113–6.
  44. de Visser KE, Eichten A, Coussens LM. Paradoxical roles of the immune system during cancer development. *Nat Rev Cancer* 2006;6:24–37.
  45. Li Q, Withoff S, Verma IM. Inflammation-associated cancer: NF- $\kappa$ B is the lynchpin. *Trends Immunol* 2005;26:318–25.
  46. Lawrence T, Hageman T, Balkwill F. Cancer, sex, cytokines, and cancer. *Science* 2007;317:51–2.
  47. Lin WW, Karin M. A cytokine-mediated link between innate immunity, inflammation, and cancer. *J Clin Invest* 2007;117:1175–83.
  48. Handisurya A, Steiner GE, Stix U, et al. Differential expression of interleukin-15, a pro-inflammatory cytokine and T-cell growth factor, and its receptor in human prostate. *Prostate* 2001;49:251–62.
  49. Kenny PA, Bissell MJ. Targeting TACE-dependent EGFR ligand shedding in breast cancer. *J Clin Invest* 2007;117:337–45.
  50. Fridman JS, Caulder E, Hansbury M, et al. Selective inhibition of ADAM metalloproteases as a novel approach for modulating ErbB pathways in cancer. *Clin Cancer Res* 2007;13:1892–902.